Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Pancreatic Neoplasms 3Neuroendocrine Tumors 3Prostatic Neoplasms 2Neoplasm Metastasis 2Multiple Myeloma 2Liver Neoplasms 2Carcinoma, Intraductal, Noninfiltrating 2Carcinoma, Hepatocellular 2Carcinoid Tumor 2Uveal Melanoma 1Thyroid Neoplasms 1Sarcoma, Synovial 1Prolactinoma 1Prolactin-Producing Pituitary Tumor 1Primary Inoperable Thymoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pituitary Neoplasms 1Peritoneal Neoplasms 1Pancreatic Fistula 1Neoplasms 1Nelson Syndrome 1Myelodysplastic Syndromes 1Meningioma 1Lymphoma 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Insulinoma 1Hypoglycemia 1Hyperinsulinism 1Hematologic Neoplasms 1

Interventions

fluorodopa F 18 4pasireotide 1Solutions 1Saline Solution 1Injections 1Furosemide 14-chloro-N-(2-furylmethyl)-5-sulfamoylanthranilic acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Congenital Hyperinsulinism × pasireotide × Clear all
NCT03053284 2021-05-14

Pasireotide in Hyperinsulinemic Hypoglycemia

Montefiore Medical Center

Phase 2 Withdrawn
Endocrine

Hyperinsulinism, Insulinoma, Congenital Hyperinsulinism

Data powered by HemOnc (CC BY 4.0) Colophon âš¡